• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
The potent oncogene NPM-ALK mediates malignant transformation of normal human CD4(+) T lymphocytes.致瘤基因 NPM-ALK 介导正常人类 CD4(+)T 淋巴细胞的恶性转化。
Am J Pathol. 2013 Dec;183(6):1971-80. doi: 10.1016/j.ajpath.2013.08.030.
2
ALK-transformed mature T lymphocytes restore early thymus progenitor features.ALK 转化的成熟 T 淋巴细胞恢复早期胸腺祖细胞特征。
J Clin Invest. 2020 Dec 1;130(12):6395-6408. doi: 10.1172/JCI134990.
3
Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target.核仁磷酸蛋白-间变性淋巴瘤激酶:终极致癌基因和治疗靶点。
Blood. 2017 Feb 16;129(7):823-831. doi: 10.1182/blood-2016-05-717793. Epub 2016 Nov 22.
4
Malignant transformation of CD4+ T lymphocytes mediated by oncogenic kinase NPM/ALK recapitulates IL-2-induced cell signaling and gene expression reprogramming.致癌激酶 NPM/ALK 介导的 CD4+ T 淋巴细胞恶性转化重现了 IL-2 诱导的细胞信号和基因表达重编程。
J Immunol. 2013 Dec 15;191(12):6200-7. doi: 10.4049/jimmunol.1300744. Epub 2013 Nov 11.
5
The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner.间变性大细胞淋巴瘤中CD30的表达由核磷蛋白-间变性淋巴瘤激酶以细胞类型特异性方式介导的JunB水平调控。
Cancer Res. 2006 Sep 15;66(18):9002-8. doi: 10.1158/0008-5472.CAN-05-4101.
6
Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1).致癌激酶NPM/ALK通过STAT3诱导免疫抑制蛋白CD274(PD-L1,B7-H1)的表达。
Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20852-7. doi: 10.1073/pnas.0810958105. Epub 2008 Dec 16.
7
Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway.与间变性大细胞淋巴瘤相关的核磷蛋白-间变性淋巴瘤激酶激活磷脂酰肌醇3-激酶/蛋白激酶B抗凋亡信号通路。
Blood. 2000 Dec 15;96(13):4319-27.
8
NPM-ALK oncogenic kinase promotes cell-cycle progression through activation of JNK/cJun signaling in anaplastic large-cell lymphoma.NPM-ALK致癌激酶通过激活间变性大细胞淋巴瘤中的JNK/cJun信号通路促进细胞周期进程。
Blood. 2007 Sep 1;110(5):1621-30. doi: 10.1182/blood-2006-11-059451. Epub 2007 Apr 6.
9
Prognostic significance of NPM-ALK fusion transcript overexpression in ALK-positive anaplastic large-cell lymphoma.NPM-ALK融合转录本过表达在ALK阳性间变性大细胞淋巴瘤中的预后意义
Mod Pathol. 2007 Jun;20(6):648-55. doi: 10.1038/modpathol.3800781. Epub 2007 Apr 20.
10
Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3.核磷蛋白/间变性淋巴瘤激酶(NPM/ALK)癌蛋白通过激活信号转导子和转录激活子3(STAT3)诱导调节性T细胞表型。
Proc Natl Acad Sci U S A. 2006 Jun 27;103(26):9964-9. doi: 10.1073/pnas.0603507103. Epub 2006 Jun 9.

引用本文的文献

1
Mediator complex subunit 1 promotes oral squamous cell carcinoma progression by activating MMP9 transcription and suppressing CD8 T cell antitumor immunity.中介复合物亚基 1 通过激活 MMP9 转录和抑制 CD8 T 细胞抗肿瘤免疫来促进口腔鳞状细胞癌的进展。
J Exp Clin Cancer Res. 2024 Sep 30;43(1):270. doi: 10.1186/s13046-024-03191-9.
2
Diverse and reprogrammable mechanisms of malignant cell transformation in lymphocytes: pathogenetic insights and translational implications.淋巴细胞恶性细胞转化的多样且可重编程机制:发病机制见解与转化意义。
Front Oncol. 2024 Apr 3;14:1383741. doi: 10.3389/fonc.2024.1383741. eCollection 2024.
3
Chimeric kinase ALK induces expression of NAMPT and selectively depends on this metabolic enzyme to sustain its own oncogenic function.嵌合激酶 ALK 诱导 NAMPT 的表达,并选择性地依赖这种代谢酶来维持其致癌功能。
Leukemia. 2023 Dec;37(12):2436-2447. doi: 10.1038/s41375-023-02038-0. Epub 2023 Sep 29.
4
Combined disruption of T cell inflammatory regulators Regnase-1 and Roquin-1 enhances antitumor activity of engineered human T cells.联合敲除 T 细胞炎症调节因子 Regnase-1 和 Roquin-1 增强了工程化人 T 细胞的抗肿瘤活性。
Proc Natl Acad Sci U S A. 2023 Mar 21;120(12):e2218632120. doi: 10.1073/pnas.2218632120. Epub 2023 Mar 15.
5
Aberrant expression of GOLM1 protects ALK+ anaplastic large cell lymphoma from apoptosis by enhancing BCL-XL stability.GOLM1 的异常表达通过增强 BCL-XL 的稳定性来保护 ALK+间变性大细胞淋巴瘤免于凋亡。
Blood Adv. 2023 Aug 8;7(15):4049-4063. doi: 10.1182/bloodadvances.2022008384.
6
Induction of Transcriptional Inhibitor HES1 and the Related Repression of Tumor-Suppressor TXNIP Are Important Components of Cell-Transformation Program Imposed by Oncogenic Kinase NPM-ALK.癌基因 NPM-ALK 诱导的转录抑制因子 HES1 的表达及其相关靶基因 TXNIP 的抑制是其导致细胞转化的重要环节。
Am J Pathol. 2022 Aug;192(8):1186-1198. doi: 10.1016/j.ajpath.2022.05.005. Epub 2022 May 28.
7
De novo generation of the NPM-ALK fusion recapitulates the pleiotropic phenotypes of ALK+ ALCL pathogenesis and reveals the ROR2 receptor as target for tumor cells.重新生成的 NPM-ALK 融合基因重现了 ALK+ ALCL 发病机制的多效性表型,并揭示了 ROR2 受体是肿瘤细胞的靶点。
Mol Cancer. 2022 Mar 4;21(1):65. doi: 10.1186/s12943-022-01520-0.
8
Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL.用于治疗儿童ALK阳性间变性大细胞淋巴瘤的靶向药物耐药性
Cancers (Basel). 2021 Nov 29;13(23):6003. doi: 10.3390/cancers13236003.
9
NPM-ALK-Induced Reprogramming of Mature TCR-Stimulated T Cells Results in Dedifferentiation and Malignant Transformation.NPM-ALK 诱导的成熟 TCR 刺激的 T 细胞重编程导致去分化和恶性转化。
Cancer Res. 2021 Jun 15;81(12):3241-3254. doi: 10.1158/0008-5472.CAN-20-2297. Epub 2021 Feb 22.
10
NPM-ALK: A Driver of Lymphoma Pathogenesis and a Therapeutic Target.NPM-ALK:淋巴瘤发病机制的驱动因素及治疗靶点
Cancers (Basel). 2021 Jan 5;13(1):144. doi: 10.3390/cancers13010144.

本文引用的文献

1
A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers.高度恶性的小儿横纹肌肉瘤的基因组基础出人意料地简单。
J Clin Invest. 2012 Aug;122(8):2983-8. doi: 10.1172/JCI64400. Epub 2012 Jul 17.
2
Expression of MALT1 oncogene in hematopoietic stem/progenitor cells recapitulates the pathogenesis of human lymphoma in mice.MALT1 癌基因在造血干/祖细胞中的表达在小鼠中再现了人类淋巴瘤的发病机制。
Proc Natl Acad Sci U S A. 2012 Jun 26;109(26):10534-9. doi: 10.1073/pnas.1204127109. Epub 2012 Jun 11.
3
ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma.间变大细胞淋巴瘤中的 ALK 信号转导与靶向治疗。
Front Oncol. 2012 May 11;2:41. doi: 10.3389/fonc.2012.00041. eCollection 2012.
4
T-cell receptor diversity prevents T-cell lymphoma development.T 细胞受体多样性可预防 T 细胞淋巴瘤发生。
Leukemia. 2012 Dec;26(12):2499-507. doi: 10.1038/leu.2012.142. Epub 2012 May 30.
5
Advancing the STATus of MPN pathogenesis.推进骨髓增殖性肿瘤发病机制的研究进展。
Blood. 2012 Apr 12;119(15):3374-6. doi: 10.1182/blood-2012-02-406611.
6
CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.CEP-28122,一种高效、选择性的间变性淋巴瘤激酶口服抑制剂,在人类癌症的实验模型中具有抗肿瘤活性。
Mol Cancer Ther. 2012 Mar;11(3):670-9. doi: 10.1158/1535-7163.MCT-11-0776. Epub 2011 Dec 27.
7
miR-135b mediates NPM-ALK-driven oncogenicity and renders IL-17-producing immunophenotype to anaplastic large cell lymphoma.miR-135b 介导 NPM-ALK 驱动的致癌性,并赋予间变性大细胞淋巴瘤产生白细胞介素-17 的免疫表型。
Blood. 2011 Dec 22;118(26):6881-92. doi: 10.1182/blood-2011-05-354654. Epub 2011 Oct 31.
8
Fusion tyrosine kinase NPM-ALK Deregulates MSH2 and suppresses DNA mismatch repair function novel insights into a potent oncoprotein.融合酪氨酸激酶 NPM-ALK 去调节 MSH2 并抑制 DNA 错配修复功能——一种潜在致癌蛋白的新见解。
Am J Pathol. 2011 Jul;179(1):411-21. doi: 10.1016/j.ajpath.2011.03.045. Epub 2011 May 24.
9
Crizotinib in anaplastic large-cell lymphoma.克唑替尼治疗间变性大细胞淋巴瘤
N Engl J Med. 2011 Feb 24;364(8):775-6. doi: 10.1056/NEJMc1013224.
10
Interaction of Epstein-Barr virus (EBV) with human B-lymphocytes.人类 B 淋巴细胞与 Epstein-Barr 病毒(EBV)的相互作用。
Biochem Biophys Res Commun. 2010 May 21;396(1):67-73. doi: 10.1016/j.bbrc.2010.02.146.

致瘤基因 NPM-ALK 介导正常人类 CD4(+)T 淋巴细胞的恶性转化。

The potent oncogene NPM-ALK mediates malignant transformation of normal human CD4(+) T lymphocytes.

出版信息

Am J Pathol. 2013 Dec;183(6):1971-80. doi: 10.1016/j.ajpath.2013.08.030.

DOI:10.1016/j.ajpath.2013.08.030
PMID:24404580
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5745542/
Abstract

With this study we have demonstrated that in vitro transduction of normal human CD4(+) T lymphocytes with NPM-ALK results in their malignant transformation. The transformed cells become immortalized and display morphology and immunophenotype characteristic of patient-derived anaplastic large-cell lymphomas. These unique features, which are strictly dependent on NPM-ALK activity and expression, include perpetual cell growth, proliferation, and survival; activation of the key signal transduction pathways STAT3 and mTORC1; and expression of CD30 (the hallmark of anaplastic large-cell lymphoma) and of immunosuppressive cytokine IL-10 and cell-surface protein PD-L1/CD274. Implantation of NPM-ALK-transformed CD4(+) T lymphocytes into immunodeficient mice resulted in formation of tumors indistinguishable from patients' anaplastic large-cell lymphomas. Our findings demonstrate that the key aspects of human carcinogenesis closely recapitulating the features of the native tumors can be faithfully reproduced in vitro when an appropriate oncogene is used to transform its natural target cells; this in turn points to the fundamental role in malignant cell transformation of potent oncogenes expressed in the relevant target cells. Such transformed cells should permit study of the early stages of carcinogenesis, and in particular the initial oncogene-host cell interactions. This experimental design could also be useful for studies of the effects of early therapeutic intervention and likely also the mechanisms of malignant progression.

摘要

通过本研究,我们证明了体外转导正常人类 CD4(+) T 淋巴细胞的 NPM-ALK 可导致其恶性转化。转化后的细胞永生化,并表现出与患者来源的间变性大细胞淋巴瘤一致的形态和免疫表型特征。这些独特的特征严格依赖于 NPM-ALK 的活性和表达,包括持续的细胞生长、增殖和存活;关键信号转导途径 STAT3 和 mTORC1 的激活;以及 CD30(间变性大细胞淋巴瘤的标志)和免疫抑制细胞因子 IL-10 和细胞表面蛋白 PD-L1/CD274 的表达。将 NPM-ALK 转化的 CD4(+) T 淋巴细胞植入免疫缺陷小鼠中,导致形成的肿瘤与患者的间变性大细胞淋巴瘤无法区分。我们的发现表明,当适当的致癌基因用于转化其自然靶细胞时,可以在体外忠实地再现密切模仿天然肿瘤特征的人类致癌作用的关键方面;这反过来又指出了在相关靶细胞中表达的强效致癌基因在恶性细胞转化中的基本作用。这些转化后的细胞应该可以允许研究癌变的早期阶段,特别是初始致癌基因-宿主细胞相互作用。这种实验设计对于研究早期治疗干预的效果以及可能的恶性进展机制也可能是有用的。